18.12.2014 • NewsBASFDede Willams

Nexam and BASF End Exclusivity Pact for Crosslinkers

Sweden's Nexam Chemical and Germany's BASF have decided not to extend the exclusivity agreement for PA 6.6 compounds containing Nexam Chemical's crosslinker. 
As part of the deal inked in February 2014, which ends in the second quarter of 2015, BASF had agreed to buy a minimum amount of the crosslinker each year, providing Nexam with an anticipated sales volume of around €1.1million. 
As reasons for the terminating the agreement, Nexam said it wanted to include PA 6.6 in projects it has with other partners.
BASF and Nexam, however, do plan to continue jointly testing their co-developed material containing the German partner's PA 6.6 and the Swedish partner's additives automotive applications. Tests are planned to begin in spring 2015.
Nexam was founded in 2009 as part of a management buy-out from Swedish chemical producer Perstorp.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read